Therapy Directory

Carboplatin clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Carboplatin as a study intervention. Browse Carboplatin recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 7:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1995

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Interventions: R-DXd, Bevacizumab, Carboplatin, Paclitaxel, Gemcitabine, Pegylated liposomal doxorubicin (PLD); Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 646 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 2
States / cities: Fountain Valley, California • Orlando, Florida

Conditions: Non-small Cell Lung Cancer
Interventions: Pembrolizumab, Carboplatin, Paclitaxel, Nab-paclitaxel, Pemetrexed, HER3-DXd; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 5
States / cities: Lexington, Kentucky • Baltimore, Maryland • Fargo, North Dakota + 2 more

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: Telisotuzumab Adizutecan, Pembrolizumab, Carboplatin, Cisplatin, Fluorouracil; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Duarte, California • Newnan, Georgia

Conditions: Urethral Neoplasms, Neoplasms, Urethral, Cancer of the Urethra, Urethral Cancer
Interventions: Gemcitabine, Carboplatin, Lenalidomide; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: SCLC
Interventions: ZL-1310, Atezolizumab, Carboplatin; Drug
Lead sponsor: Zai Lab (Shanghai) Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 339 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 11
States / cities: Duarte, California • New Haven, Connecticut • Sarasota, Florida + 8 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Gemcitabine, Paclitaxel, Intismeran autogene, Placebo; Biological · Drug · Other
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 680 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2038
U.S. locations: 54
States / cities: Gilbert, Arizona • Tucson, Arizona • Fullerton, California + 42 more

Conditions: Brain and Central Nervous System Tumors
Interventions: Induction Chemotherapy, Low-Risk Therapy, High-Risk Therapy, Intermediate-Risk Therapy; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 5 Years
Enrollment: 293 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2029
U.S. locations: 5
States / cities: Palo Alto, California • San Diego, California • Saint Paul, Minnesota + 2 more

Conditions: Non-small Cell Lung Cancer
Interventions: Pumitamig, Pembrolizumab, Carboplatin, Pemetrexed, Paclitaxel; Drug
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 1,580 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 53
States / cities: Birmingham, Alabama • Anchorage, Alaska • Concord, California + 46 more

Conditions: Non Small Cell Lung Cancer
Interventions: Sacituzumab tirumotecan, Pembrolizumab, Cisplatin, Pemetrexed, Gemcitabine, Carboplatin, Paclitaxel, Rescue medication; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 780 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2034
U.S. locations: 51
States / cities: Little Rock, Arkansas • Springdale, Arkansas • Beverly Hills, California + 41 more

Conditions: KRAS-mutant Non-small Cell Lung Cancer (NSCLC), KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC), KRAS-mutant Colorectal Cancer (CRC), Other KRAS-mutant Solid Tumors
Interventions: KST-6051, Gemcitabine/nab-paclitaxel, Cetuximab, Pembrolizumab, mFOLFOX6, FOLFIRI, Pemetrexed, Carboplatin; Drug
Lead sponsor: Kestrel Therapeutics, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 545 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 9
States / cities: Los Angeles, California • Sarasota, Florida • Tampa, Florida + 6 more

Conditions: Small Cell Lung Cancer (SCLC)
Interventions: Durvalumab 50 MG/ML; Drug
Lead sponsor: Alliance Foundation Trials, LLC.; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 6
States / cities: Chicago, Illinois • Scarborough, Maine • Boston, Massachusetts + 2 more

Conditions: Non-small Cell Lung Cancer, NSCLC
Interventions: Pembrolizumab, sac-TMT, Carboplatin, Paclitaxel, Nab-paclitaxel; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 851 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 22
States / cities: Little Rock, Arkansas • Burbank, California • San Diego, California + 17 more

About this Carboplatin clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Carboplatin as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results: Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Carboplatin.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Carboplatin clinical trials

Filter and sort this therapy

Live official records

A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)

A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)

A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors

A Study of ZL-1310 in Subjects With Small Cell Lung Cancer

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

About this Carboplatin clinical trials directory page